ArticleChemical communications (Cambridge, England)2018
Binding and neurotoxicity mitigation of toxic tau oligomers by synthetic heparin like oligosaccharides.
Article in Chemical communications (Cambridge, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A brain-derived tau oligomer polymorph is associated with cognitive resilience to Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Heparan Sulfate Proteoglycans in Tauopathy.Biomolecules · 2022Review
- The role of wild-type tau in Alzheimer's disease and related tauopathies.Journal of life sciences (Westlake Village, Calif.) · 2020Article
- Pharmacological Modulators of Tau Aggregation and Spreading.Brain sciences · 2020Review
- Modulating disease-relevant tau oligomeric strains by small molecules.The Journal of biological chemistry · 2020Article
- A synthetic heparinoid blocks Tau aggregate cell uptake and amplification.The Journal of biological chemistry · 2020Article
- The Challenge of Modulating Heparan Sulfate Turnover by Multitarget Heparin Derivatives.Molecules (Basel, Switzerland) · 2020Review
- Toxic Tau Oligomers Modulated by Novel Curcumin Derivatives.Scientific reports · 2019Article
- Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2019Article
- Heparan Sulfate as a Therapeutic Target in Tauopathies: Insights From Zebrafish.Frontiers in cell and developmental biology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Well-defined heparin like oligosaccharides up to decasaccharides were synthesized. It was discovered for the first time that heparin oligosaccharides, as short as tetrasaccharides, can bind with the most toxic tau species, i.e., tau oligomers with nM KD. The binding significantly reduced the cellular uptake of toxic tau oligomers and protected the cells from tau oligomer induced cytotoxicity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.